A5006442132- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- Sarcoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Chromatin Remodeling and Cancer
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Vascular Malformations Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Soft tissue tumor case studies
- Colorectal and Anal Carcinomas
Bayer (United States)
2020-2025
Fundación Hospital de Jove
1998
Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was evaluate the efficacy safety larotrectinib in primary central nervous system (CNS) tumors.Patients CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. endpoint investigator-assessed objective response rate (ORR).As July 2020, 33 identified (median age: 8.9 years;...
Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with efficacy in children TRK fusion tumors. We evaluated patient outcomes after elective discontinuation of larotrectinib the absence disease progression protocol-defined wait-and-see subset analysis eligible patients where treatment resumption was allowed if progressed. also assessed safety and all pediatric sarcoma. This cohort included 91 (younger than 18 years) from two clinical trials: infantile...
Abstract Infantile fibrosarcoma (IFS) is a rare pediatric cancer that typically presents early in life. Surgical resection commonly curative; however, sometimes not possible requiring additional multimodal treatment. IFS harbors fusion one of the neurotrophic receptor tyrosine kinase ( NTRK ) genes. Larotrectinib, highly selective inhibitor tropomyosin (TRK), has been shown to be well tolerated and effective children as young 1‐month old. We report case newborn treated with larotrectinib....
Here we report a case of an 11-year-old girl with inoperable tumor in the optic chiasm/hypothalamus, who experienced several progressions despite three lines chemotherapy treatment. Routine clinical examination classified as BRAF-negative pilocytic astrocytoma. Copy-number variation profiling fresh frozen material identified two duplications 9q21.32–33 leading to breakpoints within GKAP1 and NTRK2 genes. RT-PCR Sanger sequencing revealed GKAP1-NTRK2 exon 10–16 in-frame fusion, generating...
Abstract BACKGROUND Larotrectinib is the first-in-class, highly selective TRK inhibitor approved for tumor-agnostic use in patients with fusion cancer. We report data on larotrectinib-treated pediatric primary CNS tumors. METHODS Patients aged <18 years tumors enrolled two clinical trials (NCT02637687, NCT02576431) were included. Responses independent review committee (IRC)-assessed per RANO. permitted to stop larotrectinib absence of on-treatment progression (wait-and-see) and remain...
PURPOSE Neurotrophic tyrosine receptor kinase ( NTRK) gene fusions encode oncogenic, chimeric tropomyosin (TRK) proteins. Larotrectinib, an approved TRK inhibitor, is efficacious in locally advanced or metastatic (adv/met) fusion cancer. We evaluated the time from initial diagnosis to disease and initiation of larotrectinib treatment as well impact on course. MATERIALS AND METHODS Patients were grouped by prior lines therapy (0, 1-2, ≥ 3) pre-larotrectinib duration adv/met (short [< 3.5...
We evaluated in 214 patients with primary colorectal cancer the prognostic value of preoperative serum levels CEA and CA195. For these were above cutoff 6 ng/ml 31.3% patients, whereas for CA195 they higher than 12 U/ml 35.9% patients. The simultaneous use both antigens increased sensitivity to 49%, which was significantly that (p < 0.001) 0.01) taken singly. mean correlated Dukes' stage only, while there a significant correlation between 0.001), grade differentiation tumor location 0.05)....
Abstract BACKGROUND Larotrectinib is a highly selective TRK inhibitor approved for tumor-agnostic use in patients with various tumor types, including primary CNS tumors. Here, we report the independent central review and updated data on fusion-positive METHODS Patients fusion tumors enrolled two clinical trials (NCT02637687, NCT02576431) were included. Responses committee (IRC)-assessed. RESULTS As of July 2022, 41 eligible response assessment by IRC. The median age at enrollment was 11...
Abstract The outcome of pilocytic astrocytoma (PA) depends heavily on the success surgery. In cases where surgery alone is not curative, genetic analysis can be used to identify treatment targets for precision medicine. Here, we report a pediatric PA case that underwent incomplete surgical resection due tumor location. Clinical routine analyses demonstrated did carry any BRAF alteration. After postoperative surveillance, according low-grade glioma (LGG) protocol, recurrent progressions...
Abstract BACKGROUND TRK fusion proteins are oncogenic drivers of various CNS and non-CNS tumors. Larotrectinib, a highly selective FDA- EMA-approved inhibitor, demonstrated an objective response rate (ORR) 79% across cancers (Hong et al. Lancet Oncol. 2020). We report data in expanded set primary tumors treated with larotrectinib. METHODS Patients harboring NTRK gene larotrectinib two clinical trials (NCT02637687, NCT02576431) were identified. Disease status was investigator-assessed (RANO)....
Abstract INTRODUCTION: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumours. Larotrectinib, a highly selective TRK inhibitor, demonstrated an objective response rate (ORR) of 75% across 206 evaluable patients with non-primary CNS cancers (Hong et al, ASCO 2021). We report long-term data on larotrectinib-treated paediatric fusion-positive primary METHODS: Patients aged &lt;18 years tumours enrolled two clinical trials (NCT02637687,...
Abstract BACKGROUND Larotrectinib is a highly selective TRK inhibitor that demonstrated an objective response rate (ORR) of 30% and 24-week disease control (DCR) 73% across 33 evaluable adult pediatric patients with fusion primary CNS tumors, as July 2020 (Doz et al, Neuro Oncol 2021). We report updated data on expanded dataset. METHODS Patients tumors in two clinical trials (NCT02637687, NCT02576431) were included. Responses investigator-assessed. RESULTS As 2021, 38 (median age, 10.8...
Abstract Background NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a highly selective TRK inhibitor approved to treat patients with fusion cancer, an objective response rate (ORR) of 78% across multiple cancers (McDermott et al, ESMO 2020). We report updated data on pediatric fusion-positive primary Methods Patients aged &lt;18 years tumors harboring enrolled two clinical trials (NCT02637687, NCT02576431) were identified. was administered...
Abstract BACKGROUND NTRK gene fusions are oncogenic drivers in various CNS and non-CNS tumors. Larotrectinib is a first-in-class, highly selective TRK inhibitor approved for patients with fusion cancer, 75% objective response rate (ORR) 206 evaluable cancers (Hong et al, ASCO 2021). We report data on fusion-positive primary METHODS Patients tumors 2 clinical trials (NCT02637687, NCT02576431) were identified. Objective responses investigator-assessed. RESULTS As of July 2020, 33 identified...